Search research articles
Contact Us
Filters
Showing results (91-100 of 129) with videos related to
Page
of 13
Sort By:
Cancer Research Communications
|
March 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Benjamin J Solomon, Daniel S W Tan, Gilberto de Castro, et al.
JTO Clinical and Research Reports
|
September 23, 2024
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance
Malinda Itchins, Shirley Liang, Chris Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, et al.
JCO Precision Oncology
|
August 29, 2024
Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for Delivery
Kortnye Smith, Sophie O'Haire, Benjamin Markman, et al.
JTO Clinical and Research Reports
|
July 22, 2024
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
Benjamin J Solomon, Ibiayi Dagogo-Jack, Se-Hoon Lee, et al.
Future Science OA
|
November 11, 2025
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with <i>ALK</i>-positive non-small cell lung cancer
Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, et al.
The New England Journal of Medicine
|
April 10, 2024
Alectinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung Cancer
Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, et al.
The Lancet. Oncology
|
March 15, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong-Wan Kim, Ranee Mehra, Daniel S W Tan, et al.
Nature Communications
|
May 29, 2021
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Lauren Giuffrida, Kevin Sek, Melissa A Henderson, et al.
Nature Immunology
|
May 20, 2020
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity
Junyun Lai, Sherly Mardiana, Imran G House, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 129) with videos related to
Sort By:
Page
of 13
Cancer Research Communications
|
March 21, 2025
The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials
Benjamin J Solomon, Daniel S W Tan, Gilberto de Castro, et al.
JTO Clinical and Research Reports
|
September 23, 2024
ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance
Malinda Itchins, Shirley Liang, Chris Brown, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 21, 2019
<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
Alice T Shaw, Benjamin J Solomon, Benjamin Besse, et al.
JCO Precision Oncology
|
August 29, 2024
Patient Experience of Complex Genomic Sequencing Exploring Patient Preference, Barriers, and Enablers for Delivery
Kortnye Smith, Sophie O'Haire, Benjamin Markman, et al.
JTO Clinical and Research Reports
|
July 22, 2024
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial
Benjamin J Solomon, Ibiayi Dagogo-Jack, Se-Hoon Lee, et al.
Future Science OA
|
November 11, 2025
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with <i>ALK</i>-positive non-small cell lung cancer
Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, et al.
The New England Journal of Medicine
|
April 10, 2024
Alectinib in Resected <i>ALK</i>-Positive Non-Small-Cell Lung Cancer
Yi-Long Wu, Rafal Dziadziuszko, Jin Seok Ahn, et al.
The Lancet. Oncology
|
March 15, 2016
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong-Wan Kim, Ranee Mehra, Daniel S W Tan, et al.
Nature Communications
|
May 29, 2021
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
Lauren Giuffrida, Kevin Sek, Melissa A Henderson, et al.
Nature Immunology
|
May 20, 2020
Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity
Junyun Lai, Sherly Mardiana, Imran G House, et al.
Page
of 13